Initial Results and Long-Term Follow-up of Percutaneous Mitral Valvuloplasty in Patients with Pulmonary Hypertension

Ricardo A. Sarmiento, MD, FACC\textsuperscript{a,b}, Rodrigo Blanco, MD \textsuperscript{a,c}, Gerardo Gigena, MD \textsuperscript{a}, Jorge Lax, MD \textsuperscript{a}, Alejandro Garcia Escudero, MD \textsuperscript{a,c}, Federico Blanco, MD \textsuperscript{a,c}, Jorge Szarfer, MD \textsuperscript{a}, Raul Solerno, MD \textsuperscript{b}, Carlos D. Tajer, MD, FACC\textsuperscript{b}, Juan A. Gagliardi, MD, PhD \textsuperscript{a}*

\textsuperscript{a}Sección Hemodinamia, División Cardiología. Hospital General de Agudos Dr. Cosme Argerich. Buenos Aires, Argentina
\textsuperscript{b}Hospital El Crecí de Alta Complejidad en Red Dr. Néstor Kirchner, Florencio Varela, Provincia de Buenos Aires, Argentina
\textsuperscript{c}Servicio de Hemodinamia. Cardiovascular Chivilcoy. Sanatorio Chivilcoy. Chivilcoy, Provincia de Buenos Aires, Argentina

Received 7 February 2016; received in revised form 25 April 2016; accepted 26 April 2016; online published-ahead-of-print 4 June 2016

Background
Percutaneous balloon mitral valvuloplasty (PMV) is an attractive therapeutic approach in patients with mitral stenosis. The aim of this study was to assess the immediate and long-term clinical, echocardiographic and haemodynamic outcomes of PMV in patients with severe pulmonary hypertension (PAH).

Methods
Percutaneous balloon mitral valvuloplasty was performed in 157 consecutive patients; 60 patients (38.2%) had significant PAH defined as baseline pulmonary artery mean pressure (PAMP) $\geq$ 30 mm Hg (Group 1) and 97 patients (61.8%) had PAMP $\leq$ 30 mmHg (Group 2). Pulmonary artery systolic pressure (PASP), mortality, need for mitral valve replacement or new PMV, and valve restenosis were evaluated during follow-up.

Results
Mean age was 44.2 years and 88.5% (139 patients) were women. Primary success was achieved in 79.6% of the patients (125 patients) without differences between the groups. Mitral valve area increased from 0.90 cm$^2$ to 1.76 cm$^2$, PASP fell from 57 mmHg to 35 mmHg in Group 1 and from 38 mmHg to 30 mmHg in Group 2. Median PASP in Group 1 was 35, 32, 36, 38 and 34 mmHg at 12, 24, 36, 48 and 60 months. There were no significant differences in mitral valve area, PASP and clinical status between the groups.

Conclusion
Percutaneous balloon mitral valvuloplasty is a safe and effective technique for the treatment of patients with mitral stenosis and PAH. A significant decrease in pulmonary pressure was observed after valvuloplasty. Although there was a gradual decrease of MVA at long-term follow-up, most patients remained asymptomatic and PASP was stable.

Keywords
Valvuloplasty • Mitral valve stenosis • Haemodynamics • Pulmonary hypertension

Introduction
Mitral stenosis (MS) of rheumatic aetiology is still a common valve disease in developing countries \cite{1,2}. It is characterised by a limitation to left atrial emptying which causes a progressive increase in mean left atrial pressure and pulmonary vascular bed pressures with development of pulmonary hypertension (PAH) and increased right ventricular (RV) pressure which influences the clinical manifestations and prognosis of the disease.

\textsuperscript{a}Corresponding author at: Av. Alte. Brown 240 2 piso. (C1155ADP) Buenos Aires, Argentina, Tel.:fax: +54-11-4121-0873, Email: jgagliardi@intramed.net
© 2016 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.
Material and Methods

From January 1991 to December 2013, 157 patients with moderate to severe MS who underwent PMV were retrospectively enrolled. Patients were included if they met the following criteria: a) New York Heart Association (NYHA) functional class II or greater, in spite of optimal medical treatment; b) favourable anatomy by echocardiography (those patients with an unfavourable echocardiographic score were considered candidates for PMV according to their personal risk/benefit ratio); c) absence of contraindications for transseptal catheterisation; d) lack of grade ≥ II mitral regurgitation according to Sellers classification [13], and absence of concomitant valve disease requiring surgical treatment.

All patients gave their written informed consent to undergo the procedure and the study protocol. The study was conducted following the recommendations of the Declaration of Helsinki and was approved by the Committee on Ethics of our institution.

All the patients underwent transthoracic echocardiography before PMV, to evaluate mitral valve anatomy according to the Wilkins scoring system [14]. The mitral valve area (MVA) was determined by the pressure half-time method described by Hatle et al. [15] In patients with atrial fibrillation five cycles were averaged. After measuring the maximal velocity of the tricuspid regurgitation jet, pulmonary artery systolic pressure (PASP) was estimated using Bernoulli’s equation in which right ventricular-right atrial gradient is added to mean right atrial pressure [16,17].

Transoesophageal echocardiography was performed within 72 hours before PMV to exclude left atrial thrombi.

Percutaneous balloon mitral valvuloplasty was performed using the INOUE device [18] (Toray Industries, Inc., Tokyo, Japan) in 153 patients and with the double balloon Multi-track device (NuMed, Inc., Hopkinton, NY, USA) in 4.

Right heart catheterisation was performed with balloon flow directed Swan-Ganz catheter and the following parameters were determined before and after the procedure: PASP, mean pulmonary artery pressure (PAMP), pulmonary artery diastolic pressure (PADP), pulmonary capillary wedge pressure (PCWP), right atrial pressure, RV pressure, cardiac output, trans-pulmonary pressure gradient (TPG, defined as the difference between PAMP and PCWP) and diastolic pulmonary vascular pressure gradient (DPG, defined as the difference between PADP and PCWP). Oxygen content was analysed from blood samples.

Patients were divided in two groups according to the PAMP measured by right heart catheterisation immediately before PMV: Group 1, patients with severe pulmonary artery hypertension (PAH), defined as PAMP ≥ 30 mm Hg, and Group 2: patients with PAMP ≤ 30 mmHg.

After PMV, left ventriculography was carried out to determine the presence and degree of mitral regurgitation.

Mitral valve area was assessed by Doppler echocardiography using the Gorlin method in the catheter laboratory immediately after the procedure, 72 hours later and during follow-up. Restenosis (Rs) was defined as loss of >50% of the initial gain of MVA by the preceding PMV with a final MVA <1.5 cm² [19,20].

Clinical and echocardiographic follow-up was performed during hospitalisation, at 1, 6 and 12 months and annually thereafter. Median follow-up was 48 months (24-84 months). Pulmonary artery pressure values were obtained only by echocardiography to avoid repeating catheterisations, as there was a very close correlation between the values obtained by this method and the baseline right heart catheterisation.

The primary end-points of the study were: 1) procedure success, defined as achievement of MVA ≥1.5 cm² without major complications (mortality, mitral regurgitation >II according to Sellers classification, systemic embolism or cardiac tamponade); 2) in-hospital mortality; 3) clinical improvement defined as ≥1-point New York Heart Association functional class improvement; 4) cardiovascular mortality.

Secondary end-points were: 1) development or worsening of mitral valve regurgitation after the procedure or during follow-up; 2) procedure-related complications as needed for mitral valve replacement (MVR); 3) need for new PMV or deterioration to functional class to III or IV; and, 4) restenosis.

Statistical Analysis

Categorical variables are expressed as frequencies and percentages and were analysed by the chi square test or Fisher exact test. Continuous variables are expressed as mean ± standard deviation (SD) or median and interquartile range (IQR 25-75) and comparison of parametric and no parametric values between the two groups was performed by means of two-tailed Student t-test or Kruskal-Wallis test, as appropriate. The association between demographic, clinical and haemodynamic variables with PMV success and with the presence of PAH was evaluated. The cumulative survival curves were constructed with the Kaplan-Meier method and the Cox method was used to compare time-dependent covariates. All the calculations were performed using the Stata® 7.0 software package and a p value < 0.05 was considered statistically significant.
Results

The cohort was made up of 157 patients with MS considered candidates for PMV. Mean age was 44.2 ± 13.3 years and 139 patients (88.5%) were women. Ninety-eight patients (62.4%) were in NYHA class II, 53 patients (33.7%) in class III and 6 patients (3.8%) in class IV. Atrial fibrillation was present in 31.8% of the patients; 10 patients (6.4%) had a history of mitral commissurotomy. The clinical, echocardiographic and haemodynamic characteristics of patients are summarised in Table 1. Sixty patients (38.2%) had severe PAH (Group 1), and 97 patients (61.8%) had PAMP ≤ 30 mmHg (Group 2).

In the group of patients with PAH, mean age was 43.5 ± 14 years, 85% (51 patients) were women, 36.6% were in NYHA class III-IV and 25% presented AF. There were no differences in the clinical and demographic characteristics between groups 1 and 2.

Median MVA in Group 1 was 0.90 cm² (0.80 to 0.97 cm²), PASP assessed by right heart catheterisation was 62 mmHg (55-67), PAMP 38 mmHg, PAPD 27 mmHg, mean CWP 30 mmHg, TPG 12 mmHg (7-19) and DPG 2 mmHg (1-4); PASP assessed by Doppler echocardiography was 57 mmHg (51 to 65 mmHg); 30% of patients showed an echocardiographic Wilkins score greater than 8 and 58.3% (35 patients) had mitral regurgitation, which was mild in 97.1% of them (34 patients). There were no differences in the echocardiographic characteristics between both groups.

Percutaneous balloon mitral valvuloplasty was achieved in 125 patients (79.6%) with a median hospital stay of three days (2-8). The median MVA after PMV was 1.71 cm². The achieved MVA in the 32 patients with an unsuccessful procedure was 1.26 cm² (1.13 to 1.30).

In Group 1, the success rate was 76.6% (46 patients), with a MVA after PMV of 1.76 cm² (1.5 to 2.1). Pulmonary artery systolic pressure decreased from 62 to 35 mmHg and PCWP dropped from 25 to 16 mmHg. After PMV, 30 patients (50%) had mild (angiographic grade I) and 9 patients (15%) had moderate (angiographic grade II) mitral regurgitation. There were no statistically significant differences between both groups regarding the success rate, PASP, MVA or development of mitral regurgitation after PMV (Table 2).

Three hospital deaths (1.9%), unrelated to the presence of PAH occurred due to non-cardiac causes.

Clinical and echocardiographic follow-up was achieved in 139 patients (88.5%) with a median follow-up of 48 months (24-84 months). The median PASP in Group 1 was 35 (30-38), 32 (30-40), 36 (28.5 to 37.5), 38 (30-40) and 34 (30-41) mmHg at 12, 24, 36, 48 and 60 months, respectively (Figure 1). No significant differences were observed between both groups in the outcome of MVA and PASP. No differences were observed in PHT progression in all patients with regard to

### Table 1 Baseline demographic, clinical, echocardiographic and haemodynamic characteristics

|                  | Group 1 PAMP > 30 mmHg (n = 60) | Group 2 PAMP ≤ 30 mmHg (n = 97) | P  
|------------------|---------------------------------|---------------------------------|-----
| Age (years) (mean ± SD) | 43.5 ± 14                        | 45.4 ± 13                        | 0.52 |
| Female gender     | 51                              | 88                              | 0.31 |
| Atrial fibrillation | 15                             | 35                              | 0.16 |
| NYHA II           | 34                              | 64                              | 0.30 |
| NYHA III          | 25                              | 28                              | 0.12 |
| NYHA IV           | 1                               | 5                               | 0.40 |
| Previous PMV      | 4                               | 7                               | 1.00 |
| Previous commissurotomy | 3                           | 7                               | 0.74 |
| MVA before PMV (cm²) Median (IQR) | 0.90 (0.80-0.97) | 0.90 (0.82-1.02) | 0.29 |
| PASP (echo) before PMV (mmHg) median (IQR) | 57 (51-65) | 38 (30-43) | <0.01 |
| PASP - median (IQR) | 62 (55-67)                      | 40 (26-45)                      | <0.01 |
| dPAP - median (IQR) | 27 (21-32)                      | 18 (14-19)                      | <0.01 |
| PAMP - median (IQR) | 38 (32-40)                      | 25 (21-27)                      | <0.01 |
| PCWP (mmHg) median (IQR) | 30 (24-33) | 20 (15-26) | <0.01 |
| TPG (mmHg) median (IQR) | 12 (7-19)                      | 7 (3-9)                        | <0.01 |
| MR before PMV     | 35                              | 54                              | 0.87 |
| Wilkins score median (IQR) | 8 (6-9)                        | 7 (5-8)                        | 0.06 |
| Wilkins score >8  | 18                              | 29                              | 1.00 |

Table 2  Echocardiographic and haemodynamic results

<table>
<thead>
<tr>
<th></th>
<th>Group 1 PAMP &gt; 30 mmHg</th>
<th>Group 2 PAMP ≤ 30 mmHg</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 60)</td>
<td>(n = 97)</td>
<td></td>
</tr>
<tr>
<td>MVA after PMV (cm²)</td>
<td>1.76 (1.52 - 2.07)</td>
<td>1.71 (1.50 - 1.99)</td>
<td>0.23</td>
</tr>
<tr>
<td>Success (MVA &gt;1.5 cm²)</td>
<td>46 (76.6%)</td>
<td>79 (81.4%)</td>
<td>0.54</td>
</tr>
<tr>
<td>PASP after PMV (mmHg) (Doppler) median (IQR)</td>
<td>35 (30 - 49)</td>
<td>30 (27.7-35)</td>
<td>0.11</td>
</tr>
<tr>
<td>PASP after PMV (catheirisation) median (IQR)</td>
<td>35 (26-38)</td>
<td>27 (18-29)</td>
<td>0.35</td>
</tr>
<tr>
<td>PCWP after PMV (mmHg) median (IQR)</td>
<td>16 (12-18)</td>
<td>16 (11-17)</td>
<td>0.66</td>
</tr>
<tr>
<td>Mitral regurgitation after PMV</td>
<td>39 (65%)</td>
<td>68 (86.1%)</td>
<td>0.59</td>
</tr>
<tr>
<td>Mild MR</td>
<td>30 (50%)</td>
<td>56 (57.7%)</td>
<td>0.41</td>
</tr>
<tr>
<td>Moderate MR</td>
<td>9 (15%)</td>
<td>12 (12.3%)</td>
<td>0.81</td>
</tr>
</tbody>
</table>

MVA: mitral valve area; PMV: percutaneous balloon mitral valvuloplasty; PASP: pulmonary artery systolic pressure; PCWP: pulmonary capillary wedge pressure; MR: mitral regurgitation; IQR: interquartile range.

angiographic grades of mitral regurgitation following PMV (Figure 2).

In patients with PAH, there was a very gradual reduction in median MVA over time: 1.61 cm² (1.34 - 1.89); 1.60 cm² (1.33 - 1.89), 1.59 cm² (1.40 - 1.90), 1.56 cm² (1.32 - 1.84) and 1.50 cm² (1.34 - 1.86) at 12, 24, 36, 48 and 60 months, respectively (Figure 3). There was no association between the presence of PAH and the outcome of MVA or survival free of restenosis at follow-up (group 1: 0.87 vs. group 2: 0.76; p=0.21).

After four years of follow-up 109 patients remained asymptomatic (86.5%), 8 patients (6.3%) were on NYHA class II or III and 4 patients (3.1%) had palpitations. The number of asymptomatic patients was similar in both groups (Figure 4).

Discussion

In this study, we found that a high proportion of patients with severe MS have associated PAH. This prevalence was similar to those observed in other studies analysing the outcome of patients with PAH after PMV or surgical replacement [21–23]. Although most reports do not describe the percentage of patients with PAH, some registries with a larger number of patients showed mean or median PASP values similar to those of this study [19,24,25].

The success rate in the total population was 79.6%, a result that fits within the reported range (73 to 99%) [19–21,26].

An inverse relation has been described between the echocardiographic Wilkins score and outcome. The best immediate results were obtained in young patients with an

---

Figure 1  Evolution of the PASP after PMV and during follow-up according to the presence (Group 1) or absence (Group 2) of severe PAH.

Figure 2  Evolution of PASP in all the patients, according to the presence of mitral regurgitation (MR). MR 0: no mitral regurgitation; MR 1: mitral regurgitation grade I; MR 2: mitral regurgitation grade II.
patients with MS and PASP >100 mmHg, also have observed a decrease from 115 to 50 mmHg after surgery [28]. Although the passive component of pulmonary hypertension decreased immediately after the procedure, the regression of pulmonary vascular resistance took more time [29]. The decline of PASP in our patients with PAH was significant at six months reaching normal values at one year, and remained stable until end of follow-up; however, some studies found a gradual increase in pulmonary pressure in patients who developed restenosis [28].

We did not observe a significant relation between PAH before PMV and mortality during long-term follow-up.

The MVA showed a gradual decrease over time, which was similar in patients with and without PAH. Most registries showed a decrease of MVA in the five-year follow-up period between 0.12 to 0.20 cm², related to an increase in the rate of restenosis. Several reports showed a wide variability in the incidence of restenosis (between 3% and 70%) from one to three years of follow-up [19–22,25,30,31]. The rate of Rs in our study was 29.4% at 60 months follow-up, and was not associated with the presence of PAH. This rate is similar to that reported by Hernández et al. who observed a rate of Rs of 39% after seven years of follow-up [31]. Fawzy reported that patients with a PASP >60 mmHg before PMV, had a slight increase in the rate of Rs and events during follow-up, compared with patients with PASP <60 mmHg; however, only an echocardiographic score >8 and female gender resulted in independent predictors of Rs in this investigation [22].

**Study Limitations**

The main limitation of this study is its retrospective nature, however, complete data were obtained in all patients, and 91% completed long-term follow-up.

Pulmonary artery pressures were determined by echocardiography during follow-up and not by direct measurement due to the excellent concordance of echocardiography with the pressures recorded at the initial right heart catheterisation.

**Conclusions**

Based on the results observed, PMV is a safe and effective procedure in patients with severe PAH. The significant reduction in PASP after PMV was maintained at long-term follow-up with a significant improvement in NYHA functional class without differences between groups. Despite the gradual reduction in MVA, most patients remained asymptomatic at the end of follow-up.

**Disclosures**

No sources of external funding to declare.

**References**

Mitral Valvuloplasty in Pulmonary Hypertension


